SACRAMENTO, Calif., Dec. 27, 2017 — Dr. Chris Yu, Chief Executive Officer of international life sciences corporation Anpac Bio-Medical Science Company, announced this week surpassing a new, international record. Anpac Bio’s breakthrough, proprietary, “Cancer Differentiation Analysis” (CDA) liquid biopsy technology identified the earliest cancer and pre-cancerous disease signals in over 100 individuals previously deemed “cancer free” by other traditional, standard-of-care screening tests.
Since it’s inception, Anpac Bio has conducted general population screening to identify individuals with potential cancer risk. Among them, 100 people labeled “cancer free” by traditional, “standard-of-care” screening tests (such as imaging or annual medical check-up), were flagged by CDA at high-risk of cancer or pre-cancerous conditions. Due to the CDA results, more comprehensive medical testing was conducted; and the patients were subsequently diagnosed with early-stage disease. The CDA test caught disease signals missed by traditional screening tests.
“Our company is commemorating this holiday season by celebrating the most important gift we are able to give: the gift of life,” states Dr. Yu. “Our employees are so proud that our technology helps medical professionals identify and ‘screen out’ early stage or pre-cancerous diseases often missed by other tests. By catching these signals early, patients have the most potential medical options to successfully beat the disease; and go on to live healthy, happy lives!”
Described as “game changing”, and receiving the, “Breakthrough Innovation Award”, at the World Nobel Prize Laureate Summit; and named, “Most Promising Cancer Screening Company”, at the Global Precision Medicine Industry Awards, Anpac Bio’s CDA technology effectively reinvents early cancer screening and detection.
By analyzing simple, standard, blood tests using Anpac Bio’s proprietary, multi-level, multi-parameter, diagnostic algorithms, CDA identifies cancer with measurably-greater accuracy than most current, conventional screening methods. And it does so without any harmful side effects in patients; generating far fewer “false positives”; and at a cost substantially lower than traditional testing.
Comprehensive research validity data from 60,000+ cases demonstrate CDA consistently detects 26+ cancers — with 75%-90% sensitivity and specificity rates — usually at its earliest stages.
Pioneering “liquid biopsy” research since 2008, Anpac Bio has filed 200 CDA patent applications worldwide – 65+ issued currently; and employs over 100 globally.
“Hearing from people that beat disease because CDA caught it early is a gift we never get tired of giving!”